Assets related to Hanmi Pharm’s platform technology Orascovery, an oral drug discovery platform technology, will be transferred to C-Mer Eye Care Holdings, a Hong Kong-based healthcare company.

Athenex, Hanmi’s U.S. partner, which declared bankruptcy in May, recently signed an agreement to transfer its assets to C-Mer while in the process of liquidating the company.
As a result, Hanmi’s Orascovery and other related assets will also be transferred to C-Mer.
C-Mer is a Hong Kong-based healthcare company that provides a range of specialized services, including oncology. It owns 70 medical facilities in Ho…
Read the full article at: https://www.koreabiomed.com/news/articleView.html?idxno=21554